Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting

Thomann, Jean‐Sébastien; Heurtault, Béatrice; Weidner, Steffen M.; Brayé, Mélanie; Beyrath, Julien; Fournel, Sylvie; Schuber, Francis; Frisch, Benoı̂t

doi:10.1016/j.biomaterials.2011.03.015

Cited by 75 publications

(40 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…61 Nevertheless, many studies aiming to induce cellular responses show that physically linking the antigen and adjuvant improves T-cell responses. In addition to chemically cross-linking the components, 62,63 studies also compared the concept of packaging antigen and adjuvants into vehicles, such as polymer particles, 64,65 liposomes, 66 viruslike particles, 67 or three-dimensional scaffolds. 68 A major advantage of this approach is that the vaccine carrier content is protected from possible Representative targeting studies are grouped by vaccine design.…”

Section: Codelivery Of Antigens and Adjuvants By Suitable Vaccine Carmentioning

confidence: 99%

Targeting dendritic cells—why bother?

Kreutz

Tacken

Figdor

2013

Blood

111

View full text Add to dashboard Cite

Vaccination is among the most efficient forms of immunotherapy. Although sometimes inducing lifelong protective B-cell responses, T-cell–mediated immunity remains challenging. Targeting antigen to dendritic cells (DCs) is an extensively explored concept aimed at improving cellular immunity. The identification of various DC subsets with distinct functional characteristics now allows for the fine-tuning of targeting strategies. Although some of these DC subsets are regarded as superior for (cross-) priming of naive T cells, controversies still remain about which subset represents the best target for immunotherapy. Because targeting the antigen alone may not be sufficient to obtain effective T-cell responses, delivery systems have been developed to target multiple vaccine components to DCs. In this Perspective, we discuss the pros and cons of targeting DCs: if targeting is beneficial at all and which vaccine vehicles and immunization routes represent promising strategies to reach and activate DCs.

show abstract

Section: Codelivery Of Antigens and Adjuvants By Suitable Vaccine Carmentioning

confidence: 99%

Targeting dendritic cells—why bother?

Kreutz

Tacken

Figdor

2013

Blood

111

View full text Add to dashboard Cite

show abstract

“…In a study performed by Thomann et al, 127 mannosylated liposomes containing ErbB2/HA peptide epitopes associated with TLR agonists (TLR2/6 and TLR2/1) allowed an efficient in vivo targeting of MRs and induced prominent immune responses and tumor regression in ErbB2 expressing tumors (e.g., mouse renal carcinoma cells, RenCa). Higher efficiency was observed when TLR2/6 agonists were used as adjuvants, when compared to TLR2/1 agonists.…”

Section: Nanotechnology-mediated Passive and Active Targetingmentioning

confidence: 98%

Modulation of Dendritic Cells by Nanotechnology-Based Immunotherapeutic Strategies

Mogrão¹,

Costa²,

Gaspar³

et al. 2016

j biomed nanotechnol

View full text Add to dashboard Cite

In preceding decades, different mechanisms have been proposed to "instruct" dendritic cells (DCs) to induce immune responses against tumor antigens (TAs), thus breaking immune tolerance. Immunotherapy has been, for the last two decades, an attractive and promising therapeutic approach to fight cancer. This review will approach the nature of the immune response during cancer development and its correlation with DC function, as well as cancer vaccine principles and limitations. An overview of several delivery strategies used for in vivo modulation of DCs and direct activation of T cells will be provided, highlighting their advantages, limitations, and optimization strategies. This manuscript also presents a critical and systematic review of recent clinical trials that are investigating the therapeutic effect of these approaches, discussing prognostic outcomes of combined-treatment modalities.

show abstract

“…Dendritic cells have been an effective target for the delivery of vaccines as they form a part of both innate and acquired immunity and play a central role in triggering immune response after coming in contact with an antigen [118,119]. Polymeric nanoparticles such as PLGA, liposomes and virus-like nanoparticles have been studied for delivery of vaccines [120][121][122]. For example, PLGA nanoparticles have been used for mucosal immunization against hepatitis B [120].…”

Section: Nanoparticles For Vaccine Deliverymentioning

confidence: 99%

Nanoparticle-Mediated Delivery of Therapeutic Drugs

Ponnappan

Chugh

2015

Pharm Med

View full text Add to dashboard Cite

Nanotechnology-based pharmaceutics is a fast emerging field in the diagnosis and therapy of a number of human diseases, including cancer. Nanoparticles offer a stable means to achieve targeted drug delivery to various cells and tissues. They have been investigated for drug delivery to different tumor tissues, to brain where the blood-brain barrier poses a significant problem in the delivery of effective therapeutic molecules, to ocular tissues and also for eliciting immune response via delivery of vaccines. Particularly, the small size of nanoparticles facilitates their easy access to a wide range of cells and tissues. Further, the size of nanoparticles can be controlled and their surface can be modified with desired ligands and receptors to specifically target cells of interest as well as achieve controlled drug release. Research is being carried out on numerous biological and synthetic nanoparticles. Diverse strategies are being developed to improve their stability, specificity and drug delivery efficiency. Nanoparticles have been also used in conjunction with cellpenetrating peptides for efficient drug delivery. Cellpenetrating peptides serve as efficient nanocarriers owing to their inherent ability to cross the plasma membrane barrier and deliver cargo to intracellular targets. Modification of nanoparticles with cell-penetrating peptides further increases their efficacy for increased permeation into varied cells and tissues. The current review focuses on different classes of nanoparticles and their application in the treatment of several types of diseases. Key PointsNanoparticle-based therapeutic drugs are widely used for the treatment of a number of diseases, including cancer.Ease of modulation of size and tuning of the nanoparticles with various ligands make them effective for formulation into specific drugs with increased therapeutic index and reduced toxicity.Successful pre-clinical and early phase clinical trials have promised the emergence of nanocarrier-based drugs.

show abstract

Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting

Cited by 75 publications

References 39 publications

Targeting dendritic cells—why bother?

Targeting dendritic cells—why bother?

Modulation of Dendritic Cells by Nanotechnology-Based Immunotherapeutic Strategies

Nanoparticle-Mediated Delivery of Therapeutic Drugs

Contact Info

Product

Resources

About